The study represents the first part of Peregrine’s FDA approved product registration clinical trial for Cotara. The trial will enroll patients at four New Approaches to Brain Tumor Therapy (NABTT) institutions; Wake Forest University, Emory University, University of Alabama at Birmingham and University of Pennsylvania. Up to 28 patients will be enrolled in this trial.
“Glioblastoma multiforme is an aggressive and fatal cancer with few treatment options, and we are anxious to evaluate this novel study drug in patients,” said Dr Kevin Judy of the University of Pennsylvania, the Neurosurgery Chair for the study.
Glioblastoma multiforme (GBM) is the most common and clinically aggressive brain cancer and is associated with a grave prognosis. Approximately 80% of patients relapse within 6-12 months after treatment, with an overall median survival time for patients with newly diagnosed GBM of approximately 12 months.